touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study.
Questions
1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17)
2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55)
3. Could you tell us a little about the study, inclusion criteria, outcome measures and the impact on clinical practice? (01:55-04:58)
4. What is the potential for the use of trastuzumab deruxtecan in earlier treatment settings? (04:58-05:45)
Disclosures: Javier Cortes has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
